Charles River Laboratories International, Inc. (NYSE:CRL) Receives $172.31 Average Price Target from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) has been given an average rating of "Hold" by the seventeen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $171.85.

A number of analysts have recently weighed in on CRL shares. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a report on Thursday, May 8th. Morgan Stanley reduced their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $1.16 during mid-day trading on Friday, hitting $136.76. The company had a trading volume of 775,603 shares, compared to its average volume of 991,241. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $254.15. The stock's 50 day moving average price is $132.05 and its 200-day moving average price is $163.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market capitalization of $6.72 billion, a P/E ratio of 911.73, a P/E/G ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.27 earnings per share. Equities research analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after buying an additional 60,497 shares during the period. Wellington Management Group LLP boosted its position in Charles River Laboratories International by 5.1% in the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company's stock valued at $644,980,000 after buying an additional 208,586 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its position in Charles River Laboratories International by 8.0% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company's stock valued at $293,555,000 after buying an additional 144,732 shares during the period. Allspring Global Investments Holdings LLC boosted its position in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after buying an additional 47,221 shares during the period. Finally, Geode Capital Management LLC boosted its position in Charles River Laboratories International by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after buying an additional 14,787 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).